Steven Cohen Dyne Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 924,681 shares of DYN stock, worth $12.2 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
924,681
Previous 102,480
802.3%
Holding current value
$12.2 Million
Previous $3.68 Million
491.82%
% of portfolio
0.05%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$106 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$97.3 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$97.2 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$88.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$84 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $682M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...